[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tevogen Bio Holdings Inc (TVGN)

Tevogen Bio Holdings Inc (TVGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,018
  • Shares Outstanding, K 4,164
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,280 K
  • EBIT $ -16 M
  • EBITDA $ -26 M
  • 60-Month Beta 0.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.40 +50.16%
on 04/29/26
12.00 -19.92%
on 05/21/26
+1.47 (+18.06%)
since 04/22/26
3-Month
4.14 +132.39%
on 03/30/26
14.90 -35.50%
on 02/26/26
-4.43 (-31.55%)
since 02/20/26
52-Week
4.14 +132.39%
on 03/30/26
75.50 -87.27%
on 06/06/25
-51.89 (-84.37%)
since 05/22/25

Most Recent Stories

More News
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding...

TVGNW : 0.0417 (-2.80%)
TVGN : 9.61 (-16.90%)
Letter to Shareholders from CEO Dr. Ryan Saadi

WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ). Dear Shareholders, Since Tevogen’s 2024 public listing, we have remained...

TVGNW : 0.0417 (-2.80%)
TVGN : 9.61 (-16.90%)
Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that it has entered into a securities purchase agreement for...

TVGNW : 0.0417 (-2.80%)
TVGN : 9.61 (-16.90%)
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced continued progress within its artificial intelligence initiative,...

TVGNW : 0.0417 (-2.80%)
TVGN : 9.61 (-16.90%)
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen’s position in oncology, rare diseases, and medical devices Target CRO operates...

TVGNW : 0.0417 (-2.80%)
TVGN : 9.61 (-16.90%)
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) received written notice (the “Notification Letter”) from The Nasdaq...

TVGNW : 0.0417 (-2.80%)
TVGN : 9.61 (-16.90%)
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

WARREN, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that Mittul Mehta, Chief Information Officer and Head of...

TVGNW : 0.0417 (-2.80%)
TVGN : 9.61 (-16.90%)
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Lead investor confirmed his intention to maintain his current shareholdings. Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next...

TVGNW : 0.0417 (-2.80%)
TVGN : 9.61 (-16.90%)
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced performance advancements for its artificial intelligence...

TVGNW : 0.0417 (-2.80%)
TVGN : 9.61 (-16.90%)
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

WARREN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today issued a statement from Founder and CEO Dr. Ryan Saadi regarding the...

TVGNW : 0.0417 (-2.80%)
TVGN : 9.61 (-16.90%)

Business Summary

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers. Tevogen Bio Holdings Inc., formerly known as SEMPER PAR ACQ, is based in Warren, New Jersey.

See More

Key Turning Points

3rd Resistance Point 13.18
2nd Resistance Point 12.46
1st Resistance Point 11.03
Last Price 9.61
1st Support Level 8.89
2nd Support Level 8.17
3rd Support Level 6.75

See More

52-Week High 75.50
Fibonacci 61.8% 48.24
Fibonacci 50% 39.82
Fibonacci 38.2% 31.40
Last Price 9.61
52-Week Low 4.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.